COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03164512
Recruitment Status : Completed
First Posted : May 23, 2017
Last Update Posted : January 27, 2020
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
This study will evaluate the pharmacokinetics and pharmacodynamics of cannabidiol administered via inhalation and oral ingestion.

Condition or disease Intervention/treatment Phase
Cannabidiol Pharmacokinetics Drug: Oral or vaporized cannabidiol Drug: Placebo Phase 1

Detailed Description:

The proposed study will be conducted at the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU) and the Johns Hopkins Bayview Clinical Research Unit (CRU). Participants will complete 4 acute drug administration periods, each consisting of a single drug exposure followed by a 5-day observation period (3-days (58-hours) inpatient and 2-days outpatient). Biological specimens will be obtained to characterize the pharmacokinetics of THC, CBD, and their metabolites in whole blood, oral fluid, urine, and hair during this period. Each participant will receive all 4 dose conditions in a counterbalanced order using a placebo controlled within-subject crossover design. The 4 drug conditions are as follows:

  • Condition 1: Inhalation of cannabis vapor containing approximately a 20:1 ratio of CBD:THC and will be measured to deliver a target dose of 100mg CBD and 5mg THC.
  • Condition 2: Inhalation of 100mg CBD vapor.
  • Condition 3: Ingestion of 100mg CBD.
  • Condition 4: Placebo

Drug administration will be double blind and double dummy; both inhalation and oral ingestion of study drugs will occur during all 4 sessions. The order of drug administration will be counterbalanced across participants.

Research volunteers will be recruited until up to 18 participants have completed each of the four study sessions (received Conditions 1-4). Immediately before (baseline) and following each exposure, a battery of assessments including biological fluid collection and testing, subjective questionnaire administration, and performance testing will be conducted for all study participants. Post-exposure testing will be conducted in two phases: a 3-day (58 hour) residential stay, and a 2-day outpatient period, for a total of 5 days. Participants who drop out of the study prior to completion of all 4 drug conditions will be considered "incomplete" and replaced. Approximately one week (minimum of 6 days) will separate the administration of each dose.

The target demographic for study participation are healthy adults who: 1) have a history of intentionally inhaling cannabis/CBD, 2) have not used cannabis in the past month (desire is to have participants free of cannabinoids in biological matrices at the time of initial drug administration), and 3) who are not currently dependent on or seeking treatment for use of cannabis or other psychoactive drugs.

Study outcome variables include quantitative levels of CBD and its primary metabolites, THC and its primary metabolites, results of drug testing procedures conducted in accordance with current federal Mandatory Guidelines for workplace drug testing, subjective drug effect ratings, and performance on behavioral assessments. Biological specimens will be analyzed by an independent laboratory with validated analytical procedures that are specific and accurate for measurement of marijuana constituents and related metabolites. Subjective, cardiovascular and behavioral outcomes will be assessed using multiple regression analyses appropriate for repeated measures testing based on the final characteristics of the data set (e.g. normal distribution, skewness, kurtosis), and correlated with biomarker results of interest.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: placebo controlled, double-blind
Primary Purpose: Basic Science
Official Title: The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol
Actual Study Start Date : June 1, 2018
Actual Primary Completion Date : August 29, 2019
Actual Study Completion Date : January 22, 2020

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo oral and vapor
Drug: Placebo
Placebo capsule/vapor

Experimental: Vaporized High Cannabidiol Cannabis
Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
Drug: Oral or vaporized cannabidiol
Acute drug exposure

Experimental: Vaporized Cannabidiol
100mg cannabidiol in vapor
Drug: Oral or vaporized cannabidiol
Acute drug exposure

Experimental: Oral Cannabidiol
100mg oral cannabidiol
Drug: Oral or vaporized cannabidiol
Acute drug exposure

Primary Outcome Measures :
  1. THC-COOH in Urine [ Time Frame: Hour 4 ]
    THC-COOH in Urine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  1. Have provided written informed consent
  2. Be between the ages of 18 and 45
  3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
  4. Test negative for recent cannabis use in urine at the screening visit (confirmed by GC/MS laboratory test) and again upon admission for each experimental session
  5. Test negative for other drugs of abuse, including alcohol at the screening visit and upon arrival for each experimental session
  6. Demonstrate ability to expectorate 3-5 mL of "native" oral fluid over a 5-minute period
  7. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.
  8. Have a body mass index (BMI) in the range of 19 to 36 kg/m2
  9. Have head hair that is at least 4 cm (approximately one and a half inches) in length on the back of the head.
  10. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
  11. Have no allergies to any of the ingredients used to prepare cannabis brownies (chocolate, eggs, wheat, etc.).
  12. Report prior experience inhaling cannabis (either via smoking or vaporization).

Exclusion Criteria

  1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the Screening Visit;
  2. History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
  3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
  4. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
  5. Use of hemp seeds or hemp oil in any form in the past 3 months.
  6. Use of dronabinol (Marinol) within the past 6 months.
  7. History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
  8. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03164512

Layout table for location information
United States, Maryland
Johns Hopkins Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
Layout table for investigator information
Principal Investigator: Ryan Vandrey, PhD Johns Hopkins University

Layout table for additonal information
Responsible Party: Johns Hopkins University Identifier: NCT03164512    
Other Study ID Numbers: IRB00128331
First Posted: May 23, 2017    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual biological testing data will be published. Requests for additional data can be submitted to Dr. Vandrey via e-mail.
Supporting Materials: Clinical Study Report (CSR)
Time Frame: Will be available indefinitely after publication of study findings
Access Criteria: Request to the study PI

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms